Anti-inflammatory peptides from cardiac progenitors ameliorate dysfunction after myocardial infarction

Area of Science:

• Cardiology
• Regenerative Medicine
• Immunology

Background:

• Cardiac cell therapy shows promise for myocardial infarction but lacks understood mechanisms.
• Previous work identified therapeutic effects of stem cell antigen-1-positive cardiac progenitor cells.
• The specific paracrine factors and mechanisms of cardiac progenitor cell therapy remain unclear.

Purpose of the Study:

• To identify cardiac progenitor cell-specific paracrine factors.
• To elucidate the mechanism behind the beneficial effects of cardiac progenitor cell therapy.
• To investigate the role of soluble junctional adhesion molecule-A (JAM-A) in cardiac repair.

Main Methods:

• Antibody array analysis to identify secreted factors from cardiac progenitor cells.
• In vitro assays using conditioned medium and soluble JAM-A to assess neutrophil migration and motility.
• In vivo studies involving injection of cardiac progenitor cells into myocardial infarction models.
• Assessment of neutrophil infiltration, inflammatory cytokine expression, cardiac remodeling, and fibrosis.

Main Results:

• Soluble junctional adhesion molecule-A (JAM-A) was identified as abundantly secreted by cardiac progenitor cells.
• Soluble JAM-A inhibited neutrophil transendothelial migration and motility, an effect blocked by anti-JAM-A antibodies.
• Cardiac progenitor cell transplantation reduced neutrophil infiltration and inflammatory cytokine expression in infarct hearts.
• Transplantation of soluble JAM-A-expressing cardiac progenitor cells prevented cardiac remodeling and reduced fibrosis.

Conclusions:

• Soluble JAM-A secreted by cardiac progenitor cells mitigates neutrophil infiltration post-myocardial infarction.
• This mechanism ameliorates tissue damage by preventing excessive inflammation.
• Targeting JAM-A's anti-inflammatory effects presents a potential new therapeutic avenue for cardiovascular diseases.